# The Mochudi Prevention Project ART Protocol

> **NCT01583439** · NA · TERMINATED · sponsor: **Harvard School of Public Health (HSPH)** · enrollment: 11 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine

## Key facts

- **NCT ID:** NCT01583439
- **Lead sponsor:** Harvard School of Public Health (HSPH)
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09
- **Primary completion:** 2013-02
- **Final completion:** 2013-09
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Low Accrual.
- **Last updated:** 2015-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01583439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01583439, "The Mochudi Prevention Project ART Protocol". Retrieved via MORVS 2026-10-30 from https://api.morvs.ai/clinical/NCT01583439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*